⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8310124 | 0.84 | GDA (0.36) | — | |
| SCHEMBL8343167 | 0.79 | MAP2K1 (0.43) | — | |
| SCHEMBL8309980 | 0.76 | MAP2K1 (0.37) | — | |
| SCHEMBL8310807 | 0.75 | FKBP5 (0.38) | — | |
| SCHEMBL18542679 | 0.74 | MAP2K1 (0.39) | — | |
| SCHEMBL15061547 | 0.74 | MAP2K1 (0.39) | — | |
| SCHEMBL5746031 | 0.72 | GDA (0.46) | — | |
| SCHEMBL8310812 | 0.71 | ATIC (0.35) | — | |
| SCHEMBL8310151 | 0.69 | GDA (0.37) | — | |
| SCHEMBL9881673 | 0.69 | BRPF1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681503-A1 | PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA | Novartis AG (CH) | 2020-07-22 | — | — | EP | claimed |
| WO-2019053595-A1 | PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | claimed |
| EP-2807164-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2014-12-03 | — | — | EP | claimed |
| WO-2013111105-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-08-01 | — | — | WO | claimed |
| WO-2025037013-A1 | DIAGNOSTIC COMPOUNDS THAT BIND TO ALPHA-SYNUCLEIN | AC IMMUNE SA (CH) | 2025-02-20 | — | — | WO | disclosed |
| EP-4274567-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | Sumitomo Pharma Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023067483-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING AN MDM2 INHIBITOR, A BCL2 INHIBITOR AND A HYPOMETHYLATING AGENT AND USES THEREOF FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES | NOVARTIS AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022150801-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3897648-A1 | EXTENDED LOW DOSE REGIMENS FOR MDM2 INHIBITORS | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020128892-A1 | EXTENDED LOW DOSE REGIMENS FOR MDM2 INHIBITORS | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-3004109-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2015084804-A1 | COMBINATION OF MDM2 INHIBITOR AND BRAF INHIBITOR AND THEIR USE | NOVARTIS AG (CH) | 2015-06-11 | — | — | WO | disclosed |
| WO-2014191894-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| EP-1622909-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |